NCT02805244View on ClinicalTrials.gov

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Anemia of Chronic Kidney Disease

Interventions

DRUG

JTZ-951, 14C-JTZ-951

Trial Locations (1)

Unknown

Minneapolis

Sponsors

Lead Sponsor

Akros Pharma Inc.

All Listed Sponsors

lead

Akros Pharma Inc.

INDUSTRY

NCT02805244 - Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis | Biotech Hunter | Biotech Hunter